Diagnosis and management of von Willebrand disease in China

Area of Science:

• Hematology
• Medical Diagnostics
• Genetic Research

Background:

• Bleeding disorder care in China lacks centralized organization and national protocols.
• Existing hematologist and patient organizations are emerging to improve care.
• Diagnosis of von Willebrand disease (VWD) in China is in its early stages, leading to frequent misdiagnosis.

Purpose of the Study:

• To highlight the current challenges in diagnosing and managing von Willebrand disease (VWD) in China.
• To emphasize the need for improved diagnostic strategies and wider adoption of advanced testing methods.
• To assess the role of von Willebrand factor (VWF) antigen levels in VWD severity classification.

Main Methods:

• Analysis of current diagnostic practices for von Willebrand disease (VWD) in China.
• Evaluation of the utility of von Willebrand factor (VWF) antigen levels in clinical practice.
• Review of recently developed phenotypic assays and genetic testing for VWF.

Main Results:

• Assessment of von Willebrand factor (VWF) antigen levels is crucial for determining clinical severity and guiding replacement therapy.
• Current treatment options for VWD in China are limited to replacement therapy and antifibrinolytic drugs.
• New phenotypic assays and genetic testing for VWF show promise for precise diagnosis but require broader implementation.

Conclusions:

• Significant improvements are needed in the diagnostic strategy for von Willebrand disease (VWD) in China.
• Wider application of advanced phenotypic assays and genetic testing is essential for accurate VWD diagnosis.
• While most VWD patients may not require replacement therapy, precise diagnosis is key for appropriate management.